Trials / Unknown
UnknownNCT05638984
Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
A Low Dose Decitabine Combined With Tirelizumab Prospective Phase II Clinical Study Comparing Tirelizumab in Patients With Advanced Esophageal Squamous Cell Carcinoma Who Did Not Progress With First-line Immunotherapy Combined With Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of low-dose decitabine combined with tirelizumab in the treatment of patients with advanced esophageal squamous cell carcinoma who did not progress in first-line immunotherapy combined with chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine Injection | Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion |
| DRUG | tirelizumab | 10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion. |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
- First posted
- 2022-12-06
- Last updated
- 2022-12-06
Source: ClinicalTrials.gov record NCT05638984. Inclusion in this directory is not an endorsement.